Looking for alternative treatment options for your older dog? Today we are looking at 6 alternative treatment options for senior dogs that you can consider.
Special diet:. Diet therapy is one of the important ADHD alternative treatment methods. Changes in the diet may help your child to deal with allergy symptoms or migraine headaches.. Biofeedback: This ADHD alternative treatment method helps your child to control their own responsibilities. This therapy involves a large commitment from your whole family.. This ADHD alternative treatment option helps children learn coping skills and that give them a sense of control and mastery. This therapy helps to reduce stress and anger that can accompany with ADHD.. Herbal medicine: Herbs act as ADHD alternative treatment method. You can find a number of all natural herbal treatments sold in the United States for the control of ADHD in children. Herbs can help to calm your child and they play important role in memory and thinking.. Make sure that herbs you are using are pure, safe, and nontoxic. Herbs can cause side effects and can interact with other medications.. Some of the herbs as ADHD alternative ...
As Table 3 shows, Case 1 presented with significant clinical improvement in rule following and working memory overtime, Case 2 presented with significant clinical improvement in cognitive flexibility, and rule following, while Case 3 presented with significant clinical improvement in cognitive flexibility, inhibition response and speed processing. As can be seen in Table 3, Case 1 presented a significant clinical improvement in social skills and behavior regulation, Case 2 presented with significant clinical improvement in emotional regulation and social skills, while Case 3 presented significant clinical deterioration in behavior regulation, emotional regulation and social skills over time.. DiscussionCognitive functions. Cognitive function domains included verbal comprehension, perceptual reasoning and IQ. Case 1 who had a cavernous angioma on the right frontal lobe showed an improvement followed by a decrease in verbal comprehension and perceptual reasoning, the results obtained in the last ...
To examine the association between the use and timing of IFN-α2b and clinical outcomes, we analyzed in a retrospective multicenter cohort study of 446 COVID-19 patients in Hubei, China. Regression models estimated that early administration (≤5 days after admission) of IFN-α2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-α2b, whereas late administration of IFN-α2b was associated with increased mortality. Among survivors, early IFN-α2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-α2b was associated with delayed recovery. Additionally, early IFN-α2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. Administration of IFN-α2b during the early stage of COVID-19 could induce favorable clinical responses.. ...
Medication is the most important treatment for bipolar disorders. I will outline the medication listed in the textbook and state their potential side effects and limitations in point form.Drug: LithiumLithium is the first choice of treatment for bipola...
We report a case of the 59-year-old men with portal hypertension and liver cirrhosis, who developed pulmonary arterial hypertension. The first line treatment with sildenafil 20 mg 3 times daily was introduced as part of a Polish National Treatment Program. At a 6-month follow-up we noticed a significant clinical improvement: the patients exercise capacity and echocardiographic parameters were substantially better. In addition, the B-type natriuretic propeptide significantly decreased. ...
Of 242 patients in CT group and 215 patients in no CT group, stage I to IV disease were 1.7%, 38.4%, 58.7%,1.2% and 5.6%, 46%, 47%, 1.4%, respectively. Pretreatment imaging found lymph node and/or distant metastases in 43.4% and upstaged in 27.6% of patients, according to the 7th AJCC system. Treatment modifications were elicited in 21.9% of patients; RT (13.2%), CMT (4.1%) and both (4.5%). At median follow-up time of 35 months, progression-free survival (PFS) and overall survival (OS) at 3 years in CT and no CT group were 70.1% vs 74.7% (p = 0.135) and 68.3% vs 76.4% (p = 0.016). Subgroup analysis by stage showed that patients with stage II disease in CT and no CT group had no significant difference in 3-year PFS and OS; 80.3% vs 83.3% (p = 0.673) and 81.3% vs 79.7% (p = 0.802), respectively. In stage III disease, patients in both groups had no significant difference in 3-year PFS, 64.1% in CT group and 68.4% in no CT group (p = 0.187). However, the 3-year OS was significantly worse in CT ...
TY - JOUR. T1 - Lymphadenectomy in Gleason 7 prostate cancer. T2 - Adherence to guidelines and effect on clinical outcomes. AU - Chandrasekar, Thenappan. AU - Goldberg, Hanan. AU - Klaassen, Zachary W A. AU - Sayyid, Rashid K.. AU - Hamilton, Robert J.. AU - Fleshner, Neil E.. AU - Kulkarni, Girish S.. PY - 2018/1. Y1 - 2018/1. N2 - Background To examine usage trends, guideline adherence, and survival data for patients undergoing lymphadenectomy (LND) at the time of radical prostatectomy (RP) for Gleason 7 prostate cancer (PCa). Methods The SEER database was queried for all patients with nonmetastatic biopsy Gleason 7 PCa from 2004 to 2013. Distribution and trends of LND were analyzed. The Memorial-Sloan Kettering Cancer Center nomogram was applied to stratify patients based on risk of nodal disease at time of RP (,5% risk or ≥5% risk). Analyses were performed to determine covariates associated with LND receipt at time of RP and cancer-specific mortality (CSM). Results A total of 78,641 ...
Women now have the choice to be given epidural anesthesia to help with pain during active labor. Local anesthetic will be administered into the epidural space of the spine which will be given continuously through a small catheter that is left taped to the womans back. It normally takes about five to thirty minutes for the effects to be felt, at which time the legs may begin to feel heavy and pain should subside. While it is generally safe for both the woman and baby when having an epidural, there are potential side effects they should be aware of.. Low blood pressure is one of the most common effects. Intravenous fluids will be administered at the same time in order to prevent this from occurring. Another common side effect is uncontrollable shivering. However, shivering is something that can happen to a woman during labor even without receiving an epidural, so getting an warm blanket is often enough to help control the shivers.. A loss of bladder control during labor can sometimes happen ...
BACKGROUND: Myocardial infarction (MI) in the absence of electrocardiographic ST-segment elevation or new bundle branch block is the cause of hospitalization for a large and steadily increasing proportion of patients with acute ischemic chest pain. Despite its prevalence, the common demographic features, current hospital-based management, and short-term clinical outcome among patients with non-ST-segment elevation MI remain poorly defined. METHODS: A total of 183 113 patients with non-ST-segment elevation MI were identified in the National Registry of Myocardial Infarction database. Using a validated model, 43 928 patients (24.0%) were retrospectively placed in major, 34 917 (19.1%) in intermediate, and 104 268 (56.9%) in minor severity clinical event categories that included hospital death, recurrent myocardial ischemia, and nonfatal recurrent MI. RESULTS: The administration of widely available and universally recommended pharmacologic therapies, including aspirin and beta-adrenergic blocking agents,
Myself and certain member(s) of the AM community wondered if there were any potential side effects to be concerned with (or to look out for) when
Downloadable! Recently there has been a surge in econometric work focusing on estimating average treatment effects under various sets of assumptions. One strand of this literature has developed methods for estimating average treatment effects for a binary treatment under assumptions variously described as exogeneity, unconfoundedness, or selection on observables. The implication of these assumptions is that systematic (e.g., average or distributional) differences in outcomes between treated and control units with the same values for the covariates are attributable to the treatment. Recent analysis has considered estimation and inference for average treatment effects under weaker assumptions than typical of the earlier literature by avoiding distributional and functional form assumptions. Various methods of semiparametric estimation have been proposed, including estimating the unknown regression functions, matching, methods using the propensity score such as weighting and blocking, and combinations of
This is a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial to compare the efficacy and safety of Fruquintinib plus BSC versus placebo plus BSC in patients with metastatic colorectal cancer who have progressed after second-line or above standard chemotherapy. After checking eligibility criteria, subjects will be randomized into Fruquintinib plus BSC group (treatment group) or placebo plus BSC group (control group) in a ration of 2:1. Primary Efficacy Endpoint: Overall Survival (OS). Secondary Efficacy Endpoints: Progression free survival (PFS) (According to RECIST Version 1.1), Objective Response Rate (ORR), Disease Control Rate (DCR), . Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 4.0 ...
This study compared two doses of pembrolizumab (MK-3475) versus docetaxel in participants with non-small cell lung cancer (NSCLC) who had experienced disease progression after platinum-containing systemic therapy. Participants were assigned randomly to receive either pembrolizumab 2 mg/kg once every three weeks (Q3W), pembrolizumab 10 mg/kg Q3W or docetaxel 75 mg/m^2 Q3W. This study used an adaptive trial design so that the total number of participants randomized depended upon demonstration of sufficient objective responses at an interim analysis.. Based on the positive outcome of the Overall Survival (OS) analysis, Protocol Amendment 12 (effective date: 09 Dec 2015) enabled eligible participants who were allocated to docetaxel and experienced disease progression, to be permitted to crossover to receive pembrolizumab 2 mg/kg Q3W as long as Inclusion/Exclusion criteria were met. These participants were participating in the Cross-Over Phase.. The primary study hypotheses are that pembolizumab ...
Duration of response was defined as progression-free survival in responders, i.e. as the time between the start of a complete response (CR) or partial response (PR) and the start of progressive disease (PD) or patient death from any cause, whichever occurred first. Participants who did not have progression or had not died were censored at the last known time the participant was progression free. Participants who had initiated other anticancer therapy prior to progression were censored at the time when new anticancer therapy was initiated. Complete response (CR) and partial response (PR) were defined in outcome #1. Progressive disease was defined as at least a 20% increase in the sum of the longest diameters of target lesions; or the appearance of one or more new lesions; or the unequivocal progression of a non-target lesion. Response was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST ...
Buy single stage motor from single stage motor manufacturer, 27605 single stage motor manufacturers & single stage motor suppliers from China.
The 12 groups, recognized by CDRRMO, are not affiliated with any barangay and do not receive any regular funding for their efforts and operations. Disaster responders of barangays are funded from their DRRM or five percent of the internal revenue allotment.. They are vital to the CDRRMO because they augment our resources and capacity during the implementation of some programs like the City Wide Simulation Exercises and especially during times of disasters, said Lyndon Leovic Ancajas, CDRRMO training officer.. Ancajas added that volunteer responders go through trainings and drills to improve their skills and capacity.. Carlo Danilo de Leon, president of the EAGLES Disaster Rescue Group, one of the largest volunteer responder groups in the city with over 600 members, welcomed the support given to them by the CDRRMO.. These equipment will enable us to respond better and keep us safe during operations, de Leon said.. Raniel Nocom, president of another volunteer responder group called Darcom, ...
Background. Minimally invasive surgery is increasingly applied because of the proven better outcome and benefits for the patient such as less pain, shorter hospital stay, and less injury. Examples of such minimally invasive procedure include Endovascular Aortic Repair (EVAR), endovascular coiling of intracranial aneurysms, and Transcatheter Aortic Valve Implantation (TAVI). These procedures have in common that a device is transported through the iliac and aortic artery after an incision in the groin to the problematic location in the body. Unfortunately, these percutaneous procedures are associated with vascular complications of the iliac artery. These vascular complications include bleeding, vascular rupture, aneurysm spurium, ateriorvenous fistula, dissection, and embolism. There are various clinical and technical procedural parameters associated with these vascular complications. Next to these parameters, the morphology and disease of the vasculature also influence the risk of vascular ...
What are the alternative options for kidney disease with 30% kidney function ? Are dialysis and renal transplant are the only options for them ?
A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physicians Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast ...
This Phase IIIb study was conducted to evaluate the safety, efficacy and pharmacokinetics of darunavir/cobicistat 800/100 mg once daily in HIV-1-infected adults with no darunavir RAMs who also received two fully active N[t]RTIs. We showed that darunavir/cobicistat 800/150 mg once daily was well tolerated, and the pharmacokinetics, virologic and immunologic responses were consistent with previously published data for darunavir/ritonavir 800/100 mg once daily.. Through Week 24, the onset of any grade 3 or 4 AEs regardless of causality was low (6% in the overall population). Five out of 313 patients (2%), all of whom were treatment-naïve, experienced any study drug-related grade 3 AE through Weeks 24 and 48. No patients experienced grade 4 drug-related AEs. The most commonly reported AEs of all grades during the study, diarrhea, nausea, upper respiratory tract infection and headache, have all been reported previously for darunavir and cobicistat [5-8, 15, 16]. Renal laboratory assessments showed ...
DALLAS and TOKYO, Nov. 19, 2013- Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial.
Question - Took all the possible treatment for sinus. Should i go for sinus surgery? . Ask a Doctor about diagnosis, treatment and medication for Allergic rhinitis, Ask an ENT Specialist
The incidence statistics of type 2 diabetes mellitus can only be reduced if individualized comprehensive treatment is offered to each patient, but without just leaving his illness, said Felix Scott, general manager of Sanofi Mexico.. In the framework of the International Forum of Leaders in Diabetes, the director said that people with this condition should not be considered mere figures, because each of them has its own reality.. He pointed out that pharmaceutical companies need to develop innovative medicines every day to improve and facilitate therapies, as well as to guide the physician with new tools and training in digital technologies to better monitor their patients.. Although the person with diabetes, he said, should be seen as a person who is the center of all efforts, understands his needs and his individual and family environment, because there are sufficient reasons for not adhering to the treatment.. Results will not be achieved at the statistical level, if we do not achieve ...
Generally, Diabetes easily causes Kidney Failure if patients do not take timely treatments. Well then, what is the comprehensive treatment for stage 4 kidney failure caused by diabetes?
Effectiveness at end of January 2013 was estimated to be 92%.. Coverage at end of January was estimated (using SQUEAC) to be 63%.. Impact can be estimated as:. Impact = Effectiveness x Coverage = 92% x 63% = 58%. Data courtesy of ACF (Pakistan). Coverage also depends indirectly on:. Thorough case-finding and early treatment seeking: This ensures that the majority of admissions are uncomplicated incident cases, which leads to good outcomes (Figure 1). Late admission is associated with the need for inpatient care, longer treatment, defaulting, and poor treatment outcomes (e.g. nonresponse after long stays in programme or death). These can lead to poor opinions of the programme circulating in the host population, which may lead to more late presentations and admissions and a cycle of negative feedback may develop (Figure 2). A high level of compliance by both the beneficiary and the provider: This ensures that the beneficiary receives a treatment of proven efficacy leading to good outcomes and good ...
Cancer 101 is a source for all the information related to cancer. Know about the common types of cancer, diagnosis, possible treatments and prevention tips.
Question - Pain in back gums, treated with salt water. Gums swollen, throbbing, itchy. Possible treatment? . Ask a Doctor about diagnosis, treatment and medication for Back pain, Ask a Dentist
Comprehensive treatment is undertaken for the majority of patients during the early teens. Treatment aims to create a beautiful, balanced and functional
Contemporary Management of HIV: Modifying Antiretroviral Therapy in Virologically Suppressed Patients and Those with Treatment ...
therapy. Treatment was continued until disease progression, discontinuation due to adverse events, or withdrawal of consent. Randomization was stratified according to PSA doubling time (≤ 6 months or , 6 months) and use of osteoclast-targeted therapy at randomization. The primary endpoint was metastasis-free survival in the intention-to-treat population, with the presence of metastasis identified by independent central review of radiographic imaging every 16 weeks.. For the darolutamide vs placebo groups, the median age was 74 years in both, most patients were from European countries, PSA doubling time was up to 6 months in 70% vs 67%, the Eastern Cooperative Oncology Group performance status was 0 or 1 in 100% in both, 97% vs 94% were not using a bone-sparing agent at baseline, and 76% of both groups had received at least 2 previous hormonal therapies.. Metastasis-Free Survival. On independent central review, metastasis was found at baseline in 5.2% of the darolutamide group and 7.0% of the ...
TY - JOUR. T1 - A case of reductions in bone and brain metastatic foci and remarkable improvements in general condition by gefitinib administrations in a patient with non-small cell lung carcinoma of progressive stage. AU - Hirose, Masahiro. AU - Tachikawa, Soichi. AU - Horiguchi, Takahiko. AU - Kondo, Reiko. AU - Shiga, Mamoru. AU - Sasaki, Yasushi. AU - Ito, Tomohiro. AU - Fukumoto, Koji. AU - Torigoe, Hiroshi. AU - Kobayashi, Kashin. AU - Hayashi, Nobuyuki. AU - Watanabe, Yasushi. AU - Oohira, Daisuke. PY - 2005/4/7. Y1 - 2005/4/7. N2 - A 60-year-old male patient, who presented at our hospital mainly complaining of pain in the shoulders and back, was diagnosed with stage IV primary B4 pulmonary adenocarcinoma (T3N0M1 with bone and brain metastases) based on a transbronchial lung biopsy (TBLB). Although chemotherapy was conducted after radio-surgical treatment of the brain metastatic focus with the γ-knife, his joint pain and general condition were exacerbated, in addition to the occurrence ...
The purpose of the study is to compare safety and efficacy of a single dose of empegfilgrastimt a dose of 3 or 6 mg versus daily administration of filgrastim at
Purpose: This multicenter, open-label, phase II study evaluated the safety and clinical activity of axitinib, a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, 2, and 3, in patients with metastatic melanoma.. Experimental Design: Thirty-two patients with a maximum of one prior systemic therapy received axitinib at a starting dose of 5 mg twice daily. The primary endpoint was objective response rate.. Results: Objective response rate was 18.8% [95% confidence interval (CI), 7.2-36.4], comprising one complete and five partial responses with a median response duration of 5.9 months (95% CI, 5.0-17.0). Stable disease at 16 weeks was noted in six patients (18.8%), with an overall clinical benefit rate of 37.5%. Six-month progression-free survival rate was 33.9%, 1-year overall survival rate was 28.1%, and median overall survival was 6.6 months (95% CI, 5.2-9.0). The most frequently (,15%) reported nonhematologic, treatment-related adverse ...
A national, multi-center, open-label, phase IIIb trial to determine the efficacy and safety of treatment with ribociclib (LEE011) plus letrozole in women and
Randomised, double-masked, sham-controlled Phase 3b/4 study. All patients received 3 monthly IVT-AFL 2 mg injections. At Week 12, patients were randomised 1:1 into IVT-AFL plus sham PDT (IVT-AFL monotherapy) or IVT-AFL plus active PDT arms. Patients in both arms who did not qualify for rescue treatment received IVT-AFL 2 mg every 8 weeks (2q8); patients who qualified for rescue treatment received IVT-AFL 2q4 plus active or sham PDT, according to the randomisation arm, until visual and anatomical outcomes allowed for extension of the treatment interval. The primary efficacy endpoint was the mean change in BCVA in the study eye from baseline to Week 52. The secondary efficacy endpoint was the proportion of patients avoiding a moderate vision loss (≥15 letters) from baseline to Week 52. Exploratory endpoints included but were not limited to: (1) change in central subfield thickness ([CST] thickness of the central 1 mm of retina) over time; (2) proportion of patients with active polyps; (3) ...
A clinical trial of the Guardian implantable heart attack monitor made by Angel Medical Systems failed to meet its efficacy endpoint, but suggested that the device could be used to help detect silent heart attacks.. Wilmington, Del.-based AngelMed won FDA clearance a year ago for the Guardian device for patients with prior acute coronary syndrome events including myocardial infarctions or unstable angina at high risk for further ACS events. Its 907-patient Alerts study randomized patients implanted with Guardian to either six months with the alert function active for the treatment group or six months without activation for the control arm; both groups had the alert function activated after the six-month randomized stage.. The primary efficacy endpoint, a confirmed occlusive event within 7 days, was not significantly reduced for the treatment arm at 3.8%, compared with 4.9% for the control arm. The primary safety endpoint was met a 96.7% rate of freedom from device-related complications, ...
This pragmatic cluster RCT implemented in CHSs in urban China found no differential treatment effect in the primary outcome measure, HbA1c, with intervention and control groups both improving significantly. However, significant treatment effects favouring the intervention group were evident in psychological distress, systolic BP, waist circumference in men and SDSCA-Specific Diet. Two of these outcomes (psychological distress and systolic BP) were robust outcomes consistent with significant treatment effects, as supported in sensitivity analyses.. In addition to being statistically significant, the greater psychological distress observed in the control group compared with that in the intervention group is of clinical significance. The shift in the mean score for the control group at baseline from 14.97±6.24 to 17.45±8.12 at 12 months translates clinically to a shift in the mean from low risk of psychological distress (scores 10-15) to moderate risk of psychological distress (16-21).27 This ...
Background: Superiority clinical trials hold promises of impactful interventions for the future of evidence-based medicine but require extensive resources and may place study patients at risk. Advances made through cardiovascular (CV) trials in past decades have drastically improved patient outcomes, but little is known about the modern landscape of CV superiority trials and how it has evolved over time.. Methods: We performed a comprehensive search in PubMed using keywords and MeSH terms to identify all superiority CV trials with a primary clinical endpoint from January 1, 2006 to December 31, 2011 in the New England Journal of Medicine (NEJM), JAMA, and the Lancet. We used chi-square and Cochran-Armitage Trend tests to assess for statistical significance.. Results: We identified 188 trials (108 drug trials, 20 device trials and 60 others). Overall, 69 trials (36.7%) had positive results, demonstrating superiority of the new intervention for the primary endpoint, while 119 trials (63.3%) showed ...
Multiple treatment comparison (MTC) meta-analysis uses both direct (head-to-head) randomized clinical trial (RCT) evidence as well as indirect evidence from RCTs to compare the relative effectiveness of all included interventions. The methodological quality of MTCs may be difficult for clinicians to …
Lung Institute White Paper Reveals Evidence of Pulmonary Function Improvement from Stem Cell Therapy 21 Jan 2016 by Maren Auxier Lung Institute White Paper A new white paper released by the Lung Institute shows an increase of 10 percent or more in pulmonary function for 48 percent of patients tested after receiving stem cell therapy for COPD, with an overall average increase of 16 percent. TAMPA, Fla. January 26, 2016: Lung Institute doctor Jack Coleman, Jr., M.D. recently
ONGLYZA® (saxagliptin) achieves primary safety endpoint, demonstrating no increased risk for cardiovascular death, heart attack or stroke in SAVOR cardiovascular outcomes trial
TY - JOUR. T1 - Posttreatment infarct volumes when compared with 24-hour and 90-day clinical outcomes. T2 - Insights from the REVASCAT randomized controlled trial. AU - Al-Ajlan, F. S.. AU - Sultan, A. S.Al. AU - Minhas, P.. AU - Assis, Z.. AU - Miquel, M. A.De. AU - Millan, M.. AU - San Roman, L.. AU - Tomassello, A.. AU - Demchuk, A. M.. AU - Jovin, T. G.. AU - Cuadras, P.. AU - Davalos, A.. AU - Goyal, M.. AU - Menon, B. K.. N1 - Funding Information: REVASCAT was funded by a local independent Catalan institution (Fundació Ictus Malaltia Vascular) through an unrestricted grant from the manufacturer of the device (Covidien). This project has been partially supported by a grant from the Spanish Ministry of Health cofinanced by FEDER (Instituto de Salud Carlos III, RETICS-INVICTUS PLUS, RD 16/0019).. PY - 2018/1/1. Y1 - 2018/1/1. N2 - Background and Purpose: Endovascular therapy has become the standard of care for patients with disabling anterior circulation ischemic stroke due to proximal ...
The emphasis on evidence-based medical practice emerged in response to the potential hazards and inconsistencies of empirical clinical decision making and reinforced the importance of critical data interpretation. Randomized controlled trials (RCTs) remain the gold standard when performed by trained investigators blinded to treatment arms in multiple centers, with predetermined endpoints and adjudicated through independent core labs and clinical events committees (CECs). RCTs provide the most rigorous and unbiased answers for the safety and effectiveness of a study treatment versus a predefined control group in a specified population. However, there are criticisms of RCTs, including their applicability to real-world populations because of the inclusion/exclusion criteria used to limit confounding variables that would ultimately create heterogeneity in study arms and potentially drive confounding results. Additionally, RCTs are generally costly given the rigorous inclusion/exclusion requirements, ...
TY - JOUR. T1 - Network meta-analysis of antiplatelet therapy following coronary artery bypass grafting (CABG). T2 - none versus one versus two antiplatelet agents. AU - Chakos, Adam. AU - Jbara, Dean. AU - Singh, Kamal. AU - Yan, Tristan D.. AU - Tian, David H.. PY - 2018/9/1. Y1 - 2018/9/1. N2 - Background: Numerous agents have been trialed following coronary artery bypass grafting (CABG) to maintain long-term graft patency. While clear evidence exists for the use of aspirin in maintaining graft patency, the role of dual-antiplatelet therapy in CABG patients is not as well established. This network meta-analysis aimed to compare the short-term post-CABG graft patency outcomes for patients with none, one or two antiplatelet agents. Methods: Electronic databases were queried for randomized controlled trials comparing CABG graft patency rates at three months and beyond using various antiplatelet agents or placebo. Drug and graft patency data were compared using a mixed treatment comparison under ...
Impact of perioperative myocardial infarction on angiographic and clinical outcomes following coronary artery bypass grafting (from PRoject of Ex-vivo Vein graft ENgineering via Transfection [PREVENT] IV).
TY - JOUR. T1 - Long-term outcome following programmed electrical stimulation in patients with high-grade ventricular ectopy. AU - Kharsa, M. H.. AU - Gold, R. L.. AU - Moore, H.. AU - Yazaki, Y.. AU - Haffajee, C. I.. AU - Alpert, Joseph S. PY - 1988. Y1 - 1988. N2 - To determine if programmed electrical stimulation (PES) could be utilized to identify patients with high-grade ventricular ectopy at low- or high-risk for sudden cardiac death, we performed PES in 40 patients with high-grade ventricular ectopy refractory to conventional antiarrhythmic agents. Twenty-one patients had a previous myocardial infarction, five had cardiomyopathy, six had hypertension, three had valvular heart disease and five had no known structural heart disease. The mean age was 60 years (range, 18 to 76). During programmed ventricular stimulation, eight patients had inducible sustained (more than 30 seconds) monomorphic ventricular tachycardia (Group I) but in 32 patients sustained ventricular tachycardia was not ...
TY - JOUR. T1 - Factors influencing outcome in patients undergoing portal vein resection for adenocarcinoma of the pancreas. AU - Banz, V. M.. AU - Croagh, D.. AU - Coldham, C.. AU - Tanière, P.. AU - Buckels, J.. AU - Isaac, J.. AU - Mayer, Diane. AU - Muiesan, P.. AU - Bramhall, S.. AU - Mirza, D. F.. PY - 2012/1. Y1 - 2012/1. N2 - Background: Survival rates after surgery and adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDA) remain low. Selected patients with portal/superior mesenteric vein (PV) involvement undergo PV resection at pancreaticoduodenectomy (PD). This study analyses outcomes for PD with/without PV resection in patients with PDA. Methods: A retrospective analysis of prospectively collected data on patients requiring PD for histologically proven adenocarcinoma between 1/1997 and 9/2009 identified 326 patients with PDA, with 51 requiring PD with PV resection. Patients were analyzed in two groups: PD + PV resection vs. PD alone. Multivariate analysis was used to ...
In this prospective study of a large cohort of patients with primary THA, we found that after adjusting for important predictors, patients with OA had significantly better functional outcomes compared to those with RA/inflammatory arthritis at two-year follow-up. Results were notable for overall ADL limitation and key ADLs. Pain outcomes were not significantly different for OA versus RA. We also found that patients with AVN experienced better ADL outcome at two years compared to RA patients. In contrast, patients with AVN reported worse pain outcomes at five years compared to those with RA. Several findings in our study are of interest and merit further discussion.. One of the main findings of our study was that patients with OA had significantly better functional outcomes compared to those with RA at the two-year follow-up, as indicated by lower odds of overall moderate-severe ADL limitation. These findings were confirmed for patients younger and older than 65 years. To our knowledge, this is ...
TY - JOUR. T1 - Erratum to Predictive value of white blood cell subtypes for long-term outcome following myocardial infarctions [Atherosclerosis 196 (2008) 405-412]. AU - Dragu, Robert. AU - Khoury, Shafik. AU - Zuckerman, Robert. AU - Suleiman, Mahmoud. AU - Mutlak, Diab. AU - Agmon, Yoram. AU - Kapeliovich, Michael. AU - Beyar, Rafael. AU - Markiewicz, Walter. AU - Hammerman, Haim. AU - Aronson, Doron. PY - 2012/4. Y1 - 2012/4. UR - http://www.scopus.com/inward/record.url?scp=84858701209&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84858701209&partnerID=8YFLogxK. U2 - 10.1016/j.atherosclerosis.2006.11.045. DO - 10.1016/j.atherosclerosis.2006.11.045. M3 - Article. AN - SCOPUS:84858701209. VL - 221. SP - 605. JO - Atherosclerosis. JF - Atherosclerosis. SN - 0021-9150. IS - 2. ER - ...
Neoadjuvant breast cancer trials are important for speeding up the introduction of new treatments for patients with early breast cancer and for the highly productive translational research which they facilitate. Meta-analysis of trial data shows clear correlation between pathological response at surgery after neoadjuvant chemotherapy and longer-term outcomes at an individual patient level. However, this does not appear to be present on individual trial level analysis, when correlating improved outcome for the investigational arm for the primary endpoint (pathological response) with longer-term outcomes. The correlation between pathological response and longer-term outcomes in trials is dependent on many factors. These include definitions of pathological response, both complete and partial; assessment methods for pathological response at surgery; subtype and prognosis of breast cancer at diagnosis; number of patients recruited; adjuvant treatments; the mechanism of action of the investigational drug; the
The results of this study showed that, in patients with acute AC-LAO that was refractory to stentriever thrombectomy, permanent stenting achieved mTICI 2b-3 recanalization in 83.3% of cases, and the stent group had a significantly higher favorable outcome rate than the nonstent group without an increase in sICH or mortality. This suggests that permanent stenting may be a rescue treatment modality for stentriever-failed AC-LAO. The efficacy and safety of permanent stenting for recanalization of acute stroke were evaluated in several previous studies.10-14 In the era of stentriever thrombectomy, however, the efficacy of permanent stenting for stentriever-failed AC-LAO has remained unclear. To our knowledge, this is the first report comparing an SG with an NSG in patients with stentriever-failed AC-LAO, although the study performed was retrospective in nature.. In ≈30% of AC-LAO cases, stentriever thrombectomy failed to achieve mTICI 2b-3 recanalization.9 In 25.5% of the AC-LAO cases in this ...
Find Individuals Treatment Centers in Eads Memphis 32541, get help from Eads Memphis 32541 Individuals Rehab for Individuals Treatment in Eads Memphis 32541.
Migraine Rescue treatment is an integral part of effective Migraine management (such as NSAIDs). Discussion of possible migraine rescue treatments.
Comparison of one-year clinical outcomes between intravascular ultrasound-guided versus angiography-guided implantation of drug-eluting stents for left main lesions: a single-center analysis of a 1,016-patient cohort Xiao-Fei Gao,1,* Jing Kan,1,* Yao-Jun Zhang,1,2 Jun-Jie Zhang,1 Nai-Liang Tian,1 Fei Ye,1 Zhen Ge,1 Ping-Xi Xiao,1 Feng Chen,3 Gary Mintz,4 Shao-Liang Chen1 1Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, Peopleâ s Republic of China; 2Thorax Center, Erasmus Medical Center, Rotterdam, the Netherlands; 3Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Peopleâ s Republic of China; 4Division of Cardiology, Cardiovascular Research Foundation, Columbia University, New York, NY, USA *These authors contributed equally contributed to this work Background: The importance of intravascular ultrasound (IVUS)-guided stenting of the unprotected left main coronary artery (ULMCA) remains controversial
Calamine lotion is an over-the-counter (OTC) medication that can help relieve mild itchiness, or pruritus. It can be used to treat a variety of skin irritations from poison ivy and chigger bites, to minor burns. Learn more about calamine: what its made of, how to use, and potential side effects.
A Phase II, Single Arm, Multicentre Open Label Trial to Determine the Safety and Efficacy of Tisagenlecleucel in Pediatric Subjects With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma (NHL)
In conjunction with the National Multiple Sclerosis Society (NMSS) the Difficult Cases Webinar is an informal webinar designed to help clinicians, investigators, researchers and other personnel discuss difficult cases of pediatric MS or other suspected demyelinating diseases. Once a month individuals participate in a one hour call/webinar to help the presenter come up with possible diagnoses, treatments, or solutions to their difficult cases. If you are interested in joining the Difficult Cases Webinar and would like to receive reminders about upcoming calls then please contact Liz Brown ([email protected]).. Difficult Case Webinar Flyer. ...
The average treatment effect (ATE) is a measure used to compare treatments (or interventions) in randomized experiments, evaluation of policy interventions, and medical trials. The ATE measures the difference in mean (average) outcomes between units assigned to the treatment and units assigned to the control. In a randomized trial (i.e., an experimental study), the average treatment effect can be estimated from a sample using a comparison in mean outcomes for treated and untreated units. However, the ATE is generally understood as a causal parameter (i.e., an estimate or property of a population) that a researcher desires to know, defined without reference to the study design or estimation procedure. Both observational studies and experimental study designs with random assignment may enable one to estimate an ATE in a variety of ways. Originating from early statistical analysis in the fields of agriculture and medicine, the term treatment is now applied, more generally, to other fields of ...
WASHINGTON, March 22, 2016 /PRNewswire-USNewswire/ -- PCORI Board Authorizes $22 Million to Compare Treatment Options for Chronic Low Back Pain. Also...
Background: Among ambulatory patients with heart failure (HF), hospital admission is associated with higher subsequent mortality. HF is the leading cause of 30-day all-cause readmission, reduction of which is a goal of the Affordable Care Act. We examined the association of 30-day all-cause readmission with subsequent all-cause mortality in a propensity-matched cohort of hospitalized HF patients.. Methods: Of the 8049 Medicare beneficiaries hospitalized for HF and discharged alive from 106 U.S. hospitals (1998-2001), 7578 were alive 30-day post-discharge, of which 1519 had 30-day all-cause readmission. Using propensity scores for 30-day all-cause readmission, we assembled a matched cohort of 1516 pairs of patients with and without 30-day all-cause readmission, balanced on 34 baseline characteristics.. Results: During 2-12 months of post-discharge follow-up, all-cause mortality occurred in 41% and 27% of matched patients with and without 30-day all-cause readmission, respectively (HR, 1.68; 95% ...
Objectives: Prompt Mental Health Care (PMHC) is the Norwegian version of the Englands Improving Access to Psychological Therapies (IAPT). Both programs have been associated with substantial symptom reductions from pre- to post-treatment. The present study extends these findings by investigating symptom levels at 12 months post-treatment, as well as treatment outcome in relation to low- vs. high-intensity treatment forms. Design and Outcome Measures: A prospective cohort design was used. All participants (n = 1530) were asked to complete the Patient Health Questionnaire-9 (PHQ-9) and the Generalized Anxiety Disorder-7 questionnaire (GAD-7) at baseline, before each session during treatment, at final treatment, and at 12 months post-treatment. Cohens d was used as effect size measure. Sensitivity analyses were conducted to examine the impact of the high missing data rates at post-treatment (≈44%) and 12 months post-treatment (≈58%). Results: A large symptom reduction was seen from baseline to ...
TY - JOUR. T1 - Effect of In-Hospital Initiation of Lipid-Lowering Therapy on Six-Month Outcomes in Patients With Acute Ischemic Stroke or Transient Ischemic Attack. AU - Yeh, Poh Shiow. AU - Lin, Huey Juan. AU - Bai, Chyi Huey. AU - Hsieh, Fang I.. AU - Ke, Der Shin. AU - Li, Yi Heng. PY - 2010/5/15. Y1 - 2010/5/15. N2 - Early lipid-lowering therapy (LLT) has demonstrated clinical benefits in patients with acute coronary syndrome; however, little is known about early LLT in patients with stroke. We evaluated the effect of in-hospital initiation of LLT on the clinical outcomes of patients with stroke. The Taiwan Stroke Registry prospectively collected data from patients with acute ischemic stroke or transient ischemic attack. By July 31, 2008, 16,704 adult patients without previous LLT had been admitted and survived to discharge. The study end point was the composite outcome of recurrent stroke, ischemic heart disease, and all-cause death. We examined the effect of LLT at discharge on the ...
TY - JOUR. T1 - Labour Market Status at Ages 50-64 and All-Cause Mortality at Ages 65-70: A Longitudinal Study from Finland. AU - Klein, Julia. AU - Saarela, Jan. PY - 2019. Y1 - 2019. N2 - Individuals labour market status and health are known to be highly correlated. To investigate this association beyond prime working ages, we study how all-cause mortality at ages 65-70 relates to different labour market positions at ages 50-64. The data stem from random samples of the Finnish population, which make it possible to follow 33,000 individuals in the period 1987-2011. Hazard models are estimated to quantify the associations. For both men and women, disability pensioners have a hazard of dying at age 65+ that is approximately twice that of persons who were employed, and this ratio still exceeds 1.5 when socioeconomic and demographic variables are included. Also male unemployment, but not female, is associated with an elevated mortality risk, but this interrelation depends greatly on socioeconomic ...
Are patient-reported outcomes useful in post-treatment follow-up care for women with early breast cancer? A scoping review Cathrine Lundgaard Riis,1-3 Troels Bechmann,1,2 Pernille Tine Jensen,4,5 Angela Coulter,2,3,6 Karina Dahl Steffensen1-3 1Department of Oncology, Vejle Hospital, Vejle, Denmark; 2Institute of Regional Health Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; 3Center for Shared Decision Making, Vejle, Denmark; 4Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark; 5Department of Clinical Research, University of Southern Denmark, Odense, Denmark; 6Nuffield Department of Population Health, University of Oxford, Oxford, UK Background: Patient-reported outcomes (PROs) are frequently used to evaluate treatment effects and quality of life in clinical trials. The application of PROs in breast cancer clinics is evolving but their use to generate real-time information for use in follow-up care is uncommon. This proactive use
To systematically assess adherence of randomised trials in surgery to Consolidated Standards of Reporting Trials (CONSORT) guidelines for non-pharmacological treatments (NPT). Surgical trials are considered more difficult to design and execute than pharmacological trials. Furthermore, the original CONSORT statement does not address some aspects that are vital to the transparent reporting of surgical trials. The CONSORT-NPT extension was designed to address these issues but adherence in medical and surgical journals has not been assessed.Cross-sectional study.We identified eight general medical and eight surgical journals, indexed in PubMed and published in 2011, with the highest impact factors in their respective categories.Adherence to CONSORT statement and CONSORT-NPT extension items.We identified 54 surgical trials (22 published in medical journals and 32 in surgical journals). There were eight items for which there was less than 30% overall compliance (seven were specific to the CONSORT-NPT
TY - JOUR. T1 - Colorectal cancer. T2 - How emerging molecular understanding affects treatment decisions. AU - Sridharan, Meera. AU - Hubbard, Joleen M.. AU - Grothey, Axel. PY - 2014/2/15. Y1 - 2014/2/15. N2 - The medical treatment of metastatic colorectal cancer (mCRC) has advanced significantly over the last 10 years as the result of the introduction of several active cytotoxic and biologic agents into standard clinical practice. Several recent phase III trials reported median overall survival data exceeding 30 months, an achievement inconceivable only 5 years ago. The first major step forward in the medical management of mCRC was provided by the addition of irinotecan and oxaliplatin to fluorouracil-based therapy; this increased survival from about 12 months to about 20 months. The introduction of biologic agents such as vascular endothelial growth factor inhibitors and epidermal groTawth factor inhibitors further increased survival-to more than 2 years in prospective trials. Recently, an ...
TY - JOUR. T1 - Contemporary Management of Critical Limb Ischemia the BEST Is Yet to Come. AU - Laird, John R.. AU - Singh, Gagan. AU - Armstrong, Ehrin J.. PY - 2016/4/26. Y1 - 2016/4/26. KW - big data. KW - critical limb ischemia. KW - national inpatient sample. KW - peripheral artery disease. UR - http://www.scopus.com/inward/record.url?scp=84962178621&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84962178621&partnerID=8YFLogxK. U2 - 10.1016/j.jacc.2016.02.041. DO - 10.1016/j.jacc.2016.02.041. M3 - Comment/debate. VL - 67. SP - 1914. EP - 1916. JO - Journal of the American College of Cardiology. JF - Journal of the American College of Cardiology. SN - 0735-1097. IS - 16. ER - ...
Two protestors (of whom one is handicapped) injured during Fridays lathicharge were moved to Bombay Hospital from GT Hospital on Saturday after they alleged that they experienced poor treatment and negligent health care at GT Hospital, reports Karthik Balasubramanian.
TY - JOUR. T1 - A retrospective multicenter study on long-term prevalence of chronic pain after cardiac surgery. AU - Claudio, Marcassa. AU - Pompilio, Faggiano. AU - Cesare, Greco. AU - Marco, Ambrosetti. AU - Luigi, Temporelli Pier. PY - 2015/11/11. Y1 - 2015/11/11. N2 - Background There are limited data on sternotomy as a cause of chronic postsurgical pain, mainly restricted to 1 year after surgery. Aims To assess the prevalence of chronic poststernotomy pain and its interference on daily living. Methods In three groups of patients, a standardized telephone interview was obtained at 3 months (nU313), 1 year (nU313), and 3 years (nU319) following the rehabilitation program after cardiac surgery, in 11 rehabilitation centers. Presence, site, and the severity and interference of pain on selected daily living items were assessed. Results The prevalence of pain after cardiac surgery was 35.3% in the 3-month group, 26.8% in the 1-year group, and 19.8% in the 3-year group (P. AB - Background There ...
The study evaluated the effects of a combination of bariatric procedure with intensive medical therapy (IMT) versus intensive medical therapy alone based o
PURPOSE A prolonged time to treatment initiation (TTI) correlates with an adverse prognosis in different cancer types including resectable pancreatic cancer (PC). Only limited evidence on the correlation between TTI and prognosis in advanced PC exists. METHODS Consecutive PC patients (n = 368) who were diagnosed or treated at our high-volume comprehensive cancer center were included in a prospectively maintained database. We retrospectively analyzed time from first imaging showing advanced PC to initiation of palliative first-line chemotherapy. Lead time bias and waiting time paradox were addressed by landmark analysis and correlation of tumor burden with TTI. RESULTS Two hundred and ninety-seven patients met the pre-specified in- and exclusion criteria of our study. Median TTI was 29~days (range: 1-124 days). Most common reasons for prolonged TTI (, 21 days) were referral from an external treatment center (39%) and a second biopsy (31%). A TTI above the median-, 75th or 90th percentile (43 or ...
CI, confidence interval; CR, complete response; PR, partial response; SD, stable disease; NE, not estimable. i. Enhertu 6.4 mg/kg.. ii. As assessed by independent central review.. iii. ORR is (CR + PR).. iv. DCR is (CR + PR + SD).. Patients were treated with a median of two prior lines of therapy (1-6) with most receiving platinum-based chemotherapy (90.5%) and anti-PD-1 or PD-L1 treatment (54.8%). Median treatment duration was 7.76 months (0.7-14.3) with a median duration of follow-up of 8.0 months (1.4-14.2). As of data cut-off on 25 November 2019, 45.2% of patients with HER2m metastatic NSCLC remained on treatment with Enhertu.. The overall safety and tolerability profile of Enhertu in DESTINY-Lung01 was consistent with that seen in the Phase I lung cancer trial and previously reported Enhertu trials.4 The most common Grade 3 or higher treatment-emergent adverse events were decreased neutrophil count (26.2%) and anaemia (16.7%). There were five cases (11.9%) of confirmed treatment-related ...
BACKGROUND AND OBJECTIVE: Following stroke, it is common to exhibit motor impairments and decreased use of the upper limb. The objective of the present study was to evaluate forced use on arm function during the subacute phase after stroke.. DESIGN: A comparison of standard rehabilitation only and standard rehabilitation together with a restraining sling was made through a randomized, nonblinded, clinical pilot trial with assessments before intervention, after intervention, and at 1- and 3-month follow-ups.. SETTING: The present study took place at the departments of rehabilitation medicine, geriatrics, and neurology at a university hospital.. PARTICIPANTS: A convenience sample of 30 people 1 to 6 months (mean, 2.4 mo) after stroke was randomized into 2 groups (forced-use group and standard training group) of 15 people each. Twenty-six participants completed the 3-month follow-up.. INTERVENTION: All participants received their standard rehabilitation program with training 5 days per week for 2 ...
Inclusion Criteria: - Patients must have histologic evidence of relapsed or refractory B-cell ALL - Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or less - Philadelphia chromosome positive (Ph+) patients must be refractory to or intolerant of standard tyrosine kinase inhibitor therapy - Patients must be able to consume oral medication - Patients must have recovered to =, grade 1 or stabilized from the toxic effects of any prior chemotherapy (except alopecia) - Creatinine clearance (CrCL) ,= 60 mL/min/1.73 m^2 calculated by Cockcroft-Gault - Total bilirubin , 1.5 x upper limit of normal (ULN) - Negative serum or urine pregnancy test for women with child-bearing potential - Patients must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan, procedures, and laboratory testing Exclusion Criteria: - Patients must not have evidence of active central nervous system (CNS) disease - Patients must not be receiving any ...
January 26, 2018-Medtronic announced the initiation of its investigational device exemption (IDE) study that will evaluate the safety and effectiveness of the companys Abre venous self-expanding stent system in patients with iliofemoral venous outflow obstruction.. According to the company, the multicenter, single-arm study intends to enroll 200 patients with deep venous disease at up to 35 sites throughout the United States and Europe. The primary efficacy endpoint will evaluate patency at 12 months, which is defined by freedom from occlusion and freedom from clinically driven target lesion revascularization. The primary safety endpoint will evaluate the incidence of composite major adverse events at 30 days after stenting of an obstruction in the iliofemoral venous segment.. The Abre stent is premounted on a 9-F delivery system and features a nitinol stent with a triaxial shaft design. The stent utilizes an open-cell design with three connection points between the cells that are intended to ...
Purpose: To review the risk of local recurrence and impact of salvage therapy after Watch and Wait for rectal cancer with complete clinical response (cCR) after chemoradiation therapy (CRT). Methods and Materials: Patients with cT2-4N0-2M0 distal rectal cancer treated with CRT (50.4-54 Gy + 5-fluorouracil-based chemotherapy) and cCR at 8 weeks were included. Patients with cCR were enrolled in a strict follow-up program with no immediate surgery (Watch and Wait). Local recurrence-free survival was compared while taking into account Watch and Wait strategy alone and Watch and Wait plus salvage. Results: 90 of 183 patients experienced cCR at initial assessment after CRT (49%). When early tumor regrowths (up to and including the initial 12 months of follow-up) and late recurrences were considered together, 28 patients (31%) experienced local recurrence (median follow-up time, 60 months). Of those, 26 patients underwent salvage therapy, and 2 patients were not amenable to salvage. In 4 patients, ...
Furiex Pharmaceuticals has reported top-line results from the phase II trial of the investigational drug PPD-10558 in patients with statin-associated myalgia, or SAM. PPD-10558 did not meet its primary efficacy endpoint in this randomized, double-blind, proof-of-concept study. The study enrolled patients with high cholesterol and a prior history of SAM, and evaluated recurrence rates for SAM over a twelve-week treatment period across the following three different treatment regimens: placebo; PPD-10558; and atorvastatin (Lipitor). Patients did not report any significant differences in muscle symptoms, nor did they drop out due to SAM in significantly different percentages, among the three regimens. As expected, however, PPD-10558, a novel statin, did significantly lower LDL-cholesterol compared with placebo, and the compound also had a favorable safety profile.. Furiex acquired an exclusive license rights in 2007 from Ranbaxy Laboratories to develop, manufacture and market its novel statin ...
The therapeutic alliance has demonstrated an association with favorable psychotherapeutic outcomes in the treatment of eating disorders (EDs). However, questions remain about the inter-relationships between early alliance, early symptom improvement, and treatment outcome. We conducted a meta-analysis on the relations among these constructs, and possible moderators of these relations, in psychosocial treatments for EDs. Twenty studies met inclusion criteria and supplied sufficient supplementary data. Results revealed small-to-moderate effect sizes, βs = 0.13 to 0.22 (p , .05), indicating that early symptom improvement was related to subsequent alliance quality and that alliance ratings also were related to subsequent symptom reduction. The relationship between early alliance and treatment outcome was partially accounted for by early symptom improvement. With regard to moderators, early alliance showed weaker associations with outcome in therapies with a strong behavioral component relative to ...
THOUSAND OAKS, Calif., June 5, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a Phase 3, head-to-head trial which compared the efficacy and safety of denosumab versus Zometa(R) (zoledronic acid) in 1,901 patients with hormone-refractory prostate cancer and bone metastases. The study met its primary and secondary endpoints and demonstrated denosumabs superiority over Zometa in delaying or preventing skeletal related events (SREs). These statistically significant results will be presented in an oral session on June 6, 2010 at the American Society of Clinical Oncology (ASCO) 2010 Annual Meeting in Chicago (Late Breaking Abstract Number #LBA4507). In patients with skeletal metastases, the growing cancer cells weaken and destroy the bone around the tumor. This can result in a number of serious complications, collectively called SREs, comprising fracture, radiation to bone, surgery to bone or spinal cord compression. All can be serious complications for ...
September 8, 2011 , The study conducted by the Radiation Therapy Oncology Group (RTOG 9410) is the largest randomized trial to confirm the importance of administering chemotherapy and radiotherapy concurrently rather than sequentially for patients with locally-advanced non-small cell lung cancer (NSCLC).. Philadelphia, PA-Nearly 50,000 Americans are diagnosed each year with stage III or locally advanced NSCLC, for which surgery is usually not a viable treatment option. Optimizing nonsurgical treatment strategies for these patients is an ongoing research endeavor. In the August xx, 2011 issue of the Journal of the National Cancer Institute, RTOG researchers report that treating patients with concurrent chemotherapy and radiation therapy significantly increased five-year survival rates compared with treating patients with radiation therapy upon completion of chemotherapy treatment.. The significant increase in five-year survival for patients receiving concurrent versus sequential treatment ...
On July 20, 2018, the U.S. Food and Drug Administration approved ivosidenib (Tibsovo) for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test.. Approval was based on an open-label, single-arm, multicenter clinical trial (AG120-C-001, ClinicalTrials.gov identifier NCT02074839) that included 174 adult patients with relapsed or refractory AML with an IDH1 mutation confirmed using the IDH1 Assay, the FDA-approved test for selection of patients with AML for treatment with ivosidenib. Ivosidenib was given orally at a starting dose of 500 mg daily until disease progression, unacceptable toxicity, or hematopoietic stem cell transplantation. The median treatment duration was 4.1 months (range, 0.1-39.5 months). Of the 174 patients, 21 (12%) received a stem cell transplant following ivosidenib treatment.. Safety and Efficacy. Efficacy was established on the basis of the rate of complete remission plus complete ...